Clinical Trial Update: Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating osimertinib in combination with bevacizumab for patients with brain metastases from EGFR-mutant metastatic non-small cell lung…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Osimertinib (osimertinib)

Snippet

Sponsor: Qingdao Central Hospital | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: UNKNOWN